SLC2A1 and cancer: Corresponding to our biological system analysis, we propose that a combined addition of pharmacologic ascorbate and chloroquine in KRAS mutant cancer cells, with the inhibition of GLUT1 and downregulation of autophagy, might be a therapeutic approach in anti-cancer therapies.